Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
2021
December - Vol 14, No 4
September - Vol 14 No 3
June - Vol 14, No 2
March - Vol 14 No 1
2020
October/November - Vol 13 No 5
September - Vol 13 No 4
June - Vol 13 No 3
May - Vol 13 No 2
February - Vol 13 No 1
Issue Archive
Value-Based Care in Cardiometabolic Health
Special Issues
2021 Special Issues
December - Twelfth Annual Payers' Guide
August - Vol 14, Special Issue: Payers' Perspectives in Oncology
February - Vol 14, Special Issue: Payers' Perspectives in Oncology
2020 Special Issues
Supplements
Special Issue Archive
Topics
Conference Correspondent
ASCO 2020 - Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
2021
December - Vol 14, No 4
September - Vol 14 No 3
June - Vol 14, No 2
March - Vol 14 No 1
2020
October/November - Vol 13 No 5
September - Vol 13 No 4
June - Vol 13 No 3
May - Vol 13 No 2
February - Vol 13 No 1
Issue Archive
Value-Based Care in Cardiometabolic Health
Special Issues
2021 Special Issues
December - Twelfth Annual Payers' Guide
August - Vol 14, Special Issue: Payers' Perspectives in Oncology
February - Vol 14, Special Issue: Payers' Perspectives in Oncology
2020 Special Issues
Supplements
Special Issue Archive
Topics
Conference Correspondent
ASCO 2020 - Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Cholangiocarcinoma
Cholangiocarcinoma
,
FDA Approvals
,
Conference Highlights ASCO
Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Read More
Cholangiocarcinoma
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
Read More
Cholangiocarcinoma
Targeted Therapies in Cholangiocarcinoma
Read More
Cholangiocarcinoma
Surgery for Cholangiocarcinoma
Read More
Cholangiocarcinoma
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
Read More
Results 1 - 5 of 5
SUBSCRIBE
HOME
ABOUT
CONTACT US
TERMS OF USE
PRIVACY POLICY
ADVERTISING POLICY
© Amplity Health. All rights reserved.
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
AHDB
Print Edition
AHDB
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
AHDB
's
Privacy Policy
, and
AHDB
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION
